ChemotherapyFDA-approvedFirst-line
Platinum-based chemotherapy
How it works
Interferes with cell division, causing cancer cells to die.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, platinum-based chemotherapy significantly improved overall survival and delayed disease progression in patients with metastatic prostate cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Link Between Protein Expression and Platinum Sensitivity in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Genetic Variants and Lung Cancer Outcomes After Chemotherapy | Lung Cancer | review | — | Source → |
| Non-Small Cell Lung Cancer Trial in Brazil | Lung Cancer | preclinical | — | Source → |
| Cancer Researchers Study Re-Challenging a Patient with Platinum-Based Chemotherapy | Lung Cancer | observational | — | Source → |
| Testing Azenosertib for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Evaluating Rina-S Plus Standard Care for Ovarian Cancer Maintenance Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Comparing BL-B01D1 to Platinum-Based Chemotherapy for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Ovarian Cancer Study: Investigating INCB123667 vs Chemotherapy | Ovarian Cancer | phase-3 | — | Source → |
| Amivantamab Compared to Real-World Therapies in Lung Cancer Patients | Lung Cancer | phase-3 | Amivantamab-treated patients had significantly improved progression-free survival (median 6.9 vs. 2.3 months), time to next treatment (median 12.2 vs. 3.5 months), objective response rate (36.8% vs. 3.0%), and overall survival (median 23.1 vs. 7.5 months) compared to the adjusted external control group. | Source → |
| Study of Platinum in Treating Residual Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Surgery Benefits for Recurrent Ovarian Cancer Patients | Ovarian Cancer | observational | Complete macroscopic resection (R0) significantly improved survival across all surgeries, including secondary (36.6 vs. 15.3 months), tertiary (22.2 vs. 6.4 months), and quaternary (29.1 vs. 10.5 months). | Source → |
| Rare Lung Cancer Mutation Responds Poorly to Standard Treatment | Lung Cancer | observational | The median progression-free survival with first-line therapy was 7.4 months (95% CI: 3-12 months), and 9.8 months (95% CI: 3-27 months) for those receiving platinum-based chemotherapy in the first line. | Source → |
| Cost-effectiveness of sacituzumab tirumotecan in lung cancer treatment | Lung Cancer | phase-3 | — | Source → |
| Ovarian Cancer Microbiome Linked to Platinum Therapy Response | Ovarian Cancer | lab-study | — | Source → |
| Combining Atezolizumab with Bevacizumab and Chemotherapy for Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.83 (95% CI, 0.68 to 1.01; p = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) | Source → |
| Platinum-based Chemotherapy in Ovarian Cancer Patients on PARP Inhibitors | Ovarian Cancer | observational | The objective response rate was 23.3%, and the disease control rate was 43.3%. | Source → |
| Predicting Response to Platinum-Based Chemotherapy in Ovarian Cancer | Ovarian Cancer | observational | The area under the curve (AUC) was 0.917 in the internal validation set, 0.877 in the external validation set using centre D, and 0.845 in the external validation set using centre E. | Source → |
| PARP Inhibitors Improve Survival in Ovarian Cancer Patients | Ovarian Cancer | observational | Median overall survival was 82.0 months in the PARPi group vs 44.7 months in the control group. | Source → |
| Predicting Lung Cancer Treatment Outcomes with PET/CT Scans | Lung Cancer | phase-2 | The clinical combined PET/CT radiomics model achieved areas under the curve of 0.832 and 0.833 for the training and test sets, respectively. | Source → |
| New Biomarkers for Detecting Platinum Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | Both EV CFH and EV TMEM205 exhibited excellent diagnostic capability for PR as noted by receiver operating characteristic curves with area under the curve values of 0.95 and 0.84, respectively. | Source → |
| Platinum-based chemotherapy rechallenge for ovarian cancer | Ovarian Cancer | observational | The disease control rate was 80% (95% CI: 61-92). | Source → |
| US Lung Cancer Treatment Patterns Vary by Stage and Setting | Lung Cancer | observational | — | Source → |
| Predicting Ovarian Cancer Resistance to Platinum-Based Chemotherapy | Ovarian Cancer | lab-study | The model accurately predicted platinum resistance with an AUC of 0.964 (95% CI, 0.929-0.999). | Source → |
| New Treatment Options for Ovarian Cancer That Doesn't Respond to Platinum-Based Therapy | Ovarian Cancer | review | — | Source → |
| Germline Mutations Linked to Pancreatic Cancer Outcomes in Taiwanese Patients | Pancreatic Cancer | observational | Patients receiving 1L platinum-based chemotherapy exhibited a significantly longer median OS compared to those with platinum-free chemotherapy, 26.1 months versus 9.6 months. | Source → |
| New Biomarker for Ovarian Cancer Treatment Response Identified | Ovarian Cancer | lab-study | — | Source → |
| Ovarian Cancer Treatment Patterns in Argentina and Brazil | Ovarian Cancer | observational | — | Source → |
| Trabectedin's Role in Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
| Ovarian Cancer Cells Show Resistance to Platinum-Based Chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| REV7's role in pancreatic cancer treatment with platinum-based chemotherapy | Pancreatic Cancer | lab-study | REV7-deficient PDAC cell lines showed suppressed cell growth and enhanced sensitivity to cisplatin in vitro. | Source → |
| Copper Transporters in Ovarian Cancer Cells | Ovarian Cancer | review | — | Source → |
| Ovarian Cancer Treatment Options Limited for Patients with Platinum Resistance | Ovarian Cancer | review | — | Source → |
| Oxaliplatin Transfers into Human Milk, Study Finds | Colorectal Cancer | observational | — | Source → |
| Combining Traditional Chinese Medicine with Chemotherapy for Lung Cancer | Lung Cancer | meta-analysis | The combination significantly improved the objective response rate (RR = 1.27, 95% CI = 1.18-1.37), disease control rate (RR = 1.12, 95% CI = 1.08-1.15), and quality of life (RR = 1.41, 95% CI = 1.31-1.52). | Source → |
| CETN2 linked to platinum resistance in ovarian cancer | Ovarian Cancer | lab-study | — | Source → |
| PFAS Exposure Linked to Platinum Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | PDP overcomes carboplatin resistance in PFAS-exposed ovarian cancer cells. | Source → |
| Rare Pancreatic Cancers Respond Well to Platinum-Based Chemotherapy in Some Families | Pancreatic Cancer | observational | He remains alive without tumor recurrence after more than 36 months. | Source → |
| Rare Ovarian Cancer Case Shows Promise with Standard Treatment | Ovarian Cancer | observational | — | Source → |
| Platinum Agents May Help Lung Cancer Patients | Lung Cancer | observational | The platinum group showed significantly better overall survival (OS) than the non-platinum group (median OS: 21.5 vs. 10.5 months, hazard ratio [HR]: 0.54, 95% confidence interval [CI]: 0.40-0.73, p < 0.001). | Source → |
| Understanding Resistance to Platinum-Based Chemotherapy in Ovarian Cancer | Ovarian Cancer | review | — | Source → |
| Olaparib Maintenance Therapy for Ovarian Cancer Patients | Ovarian Cancer | phase-3 | Median progression-free survival was 9.2 months (95% confidence interval [CI], 7.6-10.9) in the overall population. | Source → |
| Platinum Re-Exposure in Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Combining Sintilimab and Autologous NK Cells for Lung Cancer Treatment | Lung Cancer | phase-2 | The median progression-free survival was 11.6 months, and the overall response rate was 45%. | Source → |
| Ovarian Cancer Treatment in Greece: Real-World Data | Ovarian Cancer | observational | The median progression-free survival was 18.2 months in the first-line setting and 8.8 months in the second-line setting, while the median overall survival was approximately 50 months. | Source → |
| Gene Variations and Chemotherapy Toxicity in Bangladeshi Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Ovarian Cancer Study Links Genetic Markers to Chemotherapy Response | Ovarian Cancer | lab-study | An increase in the median of progression-free survival time for carriers of the Gln allele (р=0.025) and Gln/Gln genotype (р=0.022) of the Gln399Arg XRCC1 was observed during the 19-months period after chemotherapy. | Source → |
| Guidelines for Diagnosing and Treating Ovarian Cancer in Resource-Constrained Settings | Ovarian Cancer | review | — | Source → |
| New Hope for Ovarian Cancer Treatment with Antibody-Drug Conjugates | Ovarian Cancer | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.